The Scientist

» industry and developmental biology

Most Recent

image: Research at Micro- and Nanoscales

Research at Micro- and Nanoscales

By | June 1, 2016

From whole cells to genes, closer examination continues to surprise.  

1 Comment

image: Editing Genomes to Record Cellular Histories

Editing Genomes to Record Cellular Histories

By | May 26, 2016

Researchers harness the power of genome editing to track cell lineages throughout zebrafish development.

0 Comments

image: E.U. Delays Vote on Roundup

E.U. Delays Vote on Roundup

By | May 24, 2016

Newly published research on the key ingredient in the Monsanto-made weed killer is holding up lawmakers’ decisions on whether to continue to allow its sale in Europe.

4 Comments

The US Department of Agriculture orders Santa Cruz Biotechnology to pay a $3.5 million fine and to cease selling research antibodies.

0 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Embryo Watch

Embryo Watch

By | May 5, 2016

A new culture system allows researchers to track the development of human embryos in vitro for nearly two weeks.

1 Comment

image: Cellular Pruning Follows Adult Neurogenesis

Cellular Pruning Follows Adult Neurogenesis

By | May 2, 2016

Newly formed neurons in the adult mouse brain oversprout and get cut back.

0 Comments

image: Lu on Syn Bio

Lu on Syn Bio

By | May 1, 2016

MIT researcher and Scientist to Watch Timothy Lu talks about the value of cross-disciplinary approaches in bringing synthetic biology into the clinic.

0 Comments

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. GM Mosquitoes Closer to Release in U.S.
  2. Judge Recommends Ruling to Block Internet Access to Sci-Hub
  3. Opinion: Microbiology Needs More Math
  4. Do Pathogens Gain Virulence as Hosts Become More Resistant?
RayBiotech